Dépistage du cancer du poumon : que dire à nos patient·e·s en attendant un programme organisé ? [Lung cancer screening: what can we tell our patients while we await a screening program ?]
Fiche du document
4 novembre 2020
- doi: 10.53738/REVMED.2020.16.713.2086
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2020.16.713.2086
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/33146956
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_FC6D286D8FE39
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Lung cancerCiter ce document
K. Selby et al., « Dépistage du cancer du poumon : que dire à nos patient·e·s en attendant un programme organisé ? [Lung cancer screening: what can we tell our patients while we await a screening program ?] », Serveur académique Lausannois, ID : 10.53738/REVMED.2020.16.713.2086
Métriques
Partage / Export
Résumé
The NLST study in the United States showed, in 2011, that low-dose lung CT scans can reduce lung cancer mortality but was limited in its routine recommendation by 96% of false positive screening results. The European NELSON trial, published in 2020, confirmed a 24% decrease in lung cancer mortality and, by using lung nodule volume and volume doubling time, decreased false positive results to 56% of positive tests. The implementation of screening programs is now expected in Europe, including Switzerland. In anticipation, we have developed a decision aid to present patients with the benefits (decreased lung cancer mortality), risks (false positives and indeterminate results), and uncertainties (incidental findings) of lung cancer screening.